Weiwei Guo

Weiwei Guo

Auto-generated profile, based on publicly available information

Weiwei Guo

Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
WGWeiwei Guo
Weiwei Guo
YWYue Wang
Yue Wang
MYMin Yang
Min Yang
ZWZehua Wang
Zehua Wang
YWYifei Wang
Yifei Wang
DYDa Yang
Da Yang
Through an integrative analysis of the lincRNA expression and tumor immune response in 9,626 tumor samples across 32 cancer types, we developed a lincRNA-based immune response (LIMER) score that can predict the immune cells infiltration and patient prognosis in multiple cancer types. Our analysis also identified tumor-specific lincRNAs, including EPIC1, that potentially regulate tumor immune response in multiple cancer types. Immunocompetent mouse models and in vitro co-culture assays demonstrated that EPIC1 induces tumor immune evasion and resistance to immunotherapy by suppressing tumor cell antigen presentation. Mechanistically, lincRNA EPIC1 interacts with the histone methyltransferase EZH2, leading to the epigenetic silencing of IFNGR1, TAP1/2, ERAP1/2, and MHC-I genes. Genetic and pharmacological inhibition of EZH2 abolish EPIC1’s immune-related oncogenic effect and its suppression of interferon-γ signaling. The EPIC1-EZH2 axis emerges as a potential mechanism for tumor immune evasion that can serve as therapeutic targets for immunotherapy.

9 December 2022 in Science Advances
Verified
Journal Article
Open access
YWYifei Wang
Yifei Wang
YZYueshan Zhao
Yueshan Zhao
WGWeiwei Guo
Weiwei Guo
GYGhanshyam Singh Yadav
Ghanshyam Singh Yadav
CBChetana Bhaskarla
Chetana Bhaskarla
DYDa Yang
Da Yang
The majority of lncRNAs’ roles in tumor immunology remain elusive. This project performed a CRISPR activation screening of 9744 lncRNAs in melanoma cells cocultured with human CD8+T cells. We identified 16 lncRNAs potentially regulating tumor immune response. Further integrative analysis using tumor immunogenomics data revealed thatIL10RB-DTandLINC01198are significantly correlated with tumor immune response and survival in melanoma and breast cancer. Specifically,IL10RB-DTsuppresses CD8+T cells activation via inhibiting IFN-γ–JAK–STAT1 signaling and antigen presentation in melanoma and breast cancer cells. On the other hand,LINC01198’s up-regulation sensitizes the killing of tumor cells by CD8+T cells. Mechanistically,LINC01198interacts and activates NF-κB component p65 to trigger the type I and type II interferon responses in melanoma and breast cancer cells. Our study systematically characterized novel lncRNAs involved in tumor immune response.